Abstract Library

#2946 Analysis of Factors Related to Gallstones in Patients with Neuroendocrine Tumors Treated with Long-Acting Somatostatin Analogues

Introduction: Somatostatin analogs are the backbone of neuroendocrine neoplasms treatment. Biliary stone disease is a potentially severe adverse event of somatostatin analogs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Qi Z, Zhang Y, Li Y, Shi y, Wang x,

Keywords: neuroendocrine neoplasms, somatostatin analogs, gallstone,

#2861 Targeted Next Generation Sequencing Analysis Reveals the Genetic Characteristics of Gastric Neuroendocrine Neoplasmas

Introduction: there are abundant information about the clinical therapy and pathological features of gastric neuroendocrine neoplasms (gNENs) but little about its genetic characteristics.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Chen H

Authors: Huang C, Yanfen S, Yuanliang L, Xiaowei W, Huangying T,

Keywords: gastric neuroendocrine neoplasms, SNV, CNV,

#2823 Peptide Receptor Radionuclide Therapy in Rectal Neuroendocrine Tumours

Introduction: Neuroendocrine tumours (NETs) arising from the rectum are more common in the Asian population. Current treatment options include somatostatin analogues, chemotherapy, and more recently, peptide-receptor radionuclide therapy (PRRT). Peptide receptor radionuclide therapy (PRRT) has been shown to be effective in the treatment of advanced gastroenteropancreatic (GEP) tumours with minimal adverse effects. Studies have also suggested that rectal NETs show good response to PRRT, better than GEP NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Tham W, Huang H, Tai W, Yan X, Ng C,

Keywords: Neuroendocrine tumours, PRRT,

#2800 Thymosin Beta 4 Is an Autocrine Mitogen for Neuroendocrine Tumour Cells

Introduction: The most commonly used NET marker chromogranin A, has a sensitivity between 60-90% and a specificity of less than 50%, hence better NET markers are needed. Previous secretome analysis using BON1, NCI-H727 and SHP-77 cell lines has led to the discovery of various candidate NET markers. One such marker is Thymosin Beta 4 (TB4). TB4 is a small 43 amino acid intracellular peptide first isolated from bovine thymus tissue.TB4 or its oxidised form TB4SO are thought to play a role in various aspects of cancer biology including tumour invasion, metastasis and apoptosis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Balasundaram P, Beaumont N, Liang S, Cuenco J, Lu X,

Keywords: neuroendocrine tumour, biomarkers, signalling,

#2786 Outcome of NET Liver Metastases Treated by TAE Using Microspheres

Introduction: Liver metastases are common in patients with neuroendocrine tumors (NETs), which are associated with the prognosis. Transarterial embolization (TAE) is one of the options for selective therapy in patients with multiple unresectable progressive liver metastases after chemotherapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Chen X

Authors: Chen X, Hu L,

Keywords: transarterial embolization, neuroendocrine tumors, NETs, microspheres,